Role of biomarkers in monitoring antiblastic cardiotoxicity

Journal of Cardiovascular Medicine

Volumn 17, Issue , 2016, Pages S27-S34

  Novo, Giuseppina ^a   Cadeddu, Christian ^b   Sucato, Vincenzo ^a   Pagliaro, Pasquale ^c   Romano, Silvio ^d   Tocchetti, Carlo G ^e   Zito, Concetta ^f   Longobardo, Luca ^f   Nodari, Savina ^g   Penco, Maria ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

Author keywords

antiblastic; anticancer drugs; antineoplastic; biomarkers; brain natriuretic peptide; cardiac toxicity; troponin

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; NATRIURETIC FACTOR; TROPONIN; BRAIN NATRIURETIC PEPTIDE;

ACCURACY; ARTICLE; CANCER THERAPY; CARDIOTOXICITY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; HEART MUSCLE TENSION; HUMAN; INFLAMMATION; MONITORING; OXIDATIVE STRESS; PRACTICE GUIDELINE; SENSITIVITY AND SPECIFICITY; WALL STRESS; BLOOD; EARLY DIAGNOSIS; NEOPLASMS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; NEOPLASM; PHYSIOLOGIC MONITORING;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CARDIOTOXICITY; EARLY DIAGNOSIS; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TROPONIN; CARDIOVASCULAR DISEASES; MONITORING, PHYSIOLOGIC;

EID: 84970016736     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000379     Document Type: Article

References (98)

1. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815
2. Glück S. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 2005; 10: 780-791
3. Madonna R, Cadeddu C, Deidda M, et al. Cardioprotection by gene therapy: a review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. Int J Cardiol 2015; 191: 203-210
4. Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999; 17: 3596-3602
5. Lieutaud T, Brain E, Golgran-Toledano D, et al. 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer 1996; 32A: 368-369
6. Cwikiel M, Persson SU, Larsson H, et al. Changes of blood viscosity in patients treated with 5-fluorouracil: a link to cardiotoxicity? Acta Oncol 1995; 34: 83-85
7. Piotrowski G, Gawor R, Stasiak A, et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer over expressing human epidermal growth factor receptor type 2: a prospective study. Arch Med Sci 2012; 8: 227-235
8. Di Lisi D, Bonura F, Macaione F, et al. Chemotherapy-induced cardiotoxicity: role of the conventional echocardiography and the tissue Doppler. Minerva Cardioangiol 2011; 59: 301-308
9. Morandi P, Ruffini PA, Benvenuto GM, et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323-334
10. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation 2004; 109: 3122-3131
11. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302
12. Di Lisi D, Leggio G, Vitale G, et al. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction. J Cardiovasc Med (Hagerstown) 2014. [Epub ahead of print]
13. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective blinded long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709
14. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743
15. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900-2902
16. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracyclineinduced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561-578
17. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002; 25: 301-311
18. Adamcova M, Sterba M, Simunek T, et al. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005; 4: 457-472
19. Bronte G, Bronte E, Novo G, et al. Conquests and perspectives of cardiooncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opin Drug Saf 2015; 14: 253-267
20. Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracyclineinduced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and antierbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002; 105: 1551-1554
21. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 1-10
22. Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med 2014; 16: 315
23. Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012; 52: 1213-1225
24. Salvatorelli E, Menna P, Cantalupo E, et al. The concomitant management of cancer therapy and cardiac therapy. Biochim Biophys Acta 2015; 1848: 2727-2737
25. Shalkey-Hahn V, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc 2014; 3: e000665
26. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596-603
27. Sawyer DB. Anthracyclines and heart failure. N Engl J Med 2013; 368: 1154-1156
28. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18: 1639-1642
29. Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-Analysis of incidence and clinical predictors of Anthracycline cardiotoxicity. Am J Cardiol 2013; 112: 1980-1984
30. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-Analysis of randomised controlled trials. BMC Cancer 2010; 10: 337
31. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 1978; 240: 1603-1606
32. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-242
33. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumabrelated cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7826
34. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma. An expanded-Access trial. Lancet Oncol 2009; 10: 757-763
35. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol 2010; 28: 3901-3904
36. Tocchetti CG, Ragone G, Coppola C, et al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail 2012; 14: 130-137
37. Tocchetti CG, Gallucci G, Coppola C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail 2013; 15: 482-489
38. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286
39. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23 (Suppl 7): vii155-vii166
40. Marone G, Granata F. Angiogenesis lymphangiogenesis and clinical implications. Preface. Chem Immunol Allergy 2014; 99: XI-XI10
41. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
42. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355: 2542-2550
43. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019
44. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500-2508
45. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124
46. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19: 1613-1618
47. Aparicio-Gallego G, Afonso-Afonso FJ, Leó n-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 2011; 22: 1-8
48. De Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD.Management of antiangiogenic therapy-induced hypertension. Hypertension 2012; 60: 607-615
49. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513
50. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expertconsensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012; 60: 2427-2463
51. O?Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008; 245: 206-218
52. Dhesy-Thind S, Kumar V, Snider-McNair A, et al. Cardiac and inflammation biomarker profile after initiation of adjuvant trastuzumab therapy. Clin Chem 2013; 59: 327-329
53. Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem 2015; 48: 223-235
54. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicintreated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11: 950-961
55. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30: 1042-1049
56. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710-715
57. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754
58. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218-222
59. Feola M, Garrone O, Occelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011; 148: 194-198
60. Mercuro G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007; 12: 1124-1233
61. Romano S, Fratini S, Ricevuto E, et al. Serial measurements of NT-proBNP are predictive of not high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105: 1663-1668
62. Pistillucci G, Ciorra AA, Sciacca V, et al. Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab. Clin Ter 2015; 166: e67-e71
63. Singh D, Thakur A, Tang WH. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy. Curr Heart Fail Rep 2015; 12: 255-262
64. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-3916
65. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-5212
66. Ederhy S, Massard C, Dufaitre G, et al. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Invest New Drugs 2012; 30: 611-615
67. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. noncoronary disease. Eur Heart J 2011; 32: 404-411
68. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710-715
69. Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (Suppl 5): v277-v282
70. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1063-1093
71. Chowdhury P, Kehl D, Choudhary R, Maisel A. The use of biomarkers in the patient with heart failure. Curr Cardiol Rep 2013; 15: 372-377
72. Novo G, Amoroso GR, Fazio G, et al. Biomarkers in heart failure. Front Biosci (Landmark Ed) 2009; 14: 2484-2493
73. Latour-Pé rez J, Coves-Orts FJ, Abad-Terrado C, et al. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail 2006; 8: 390-399
74. Romano S, Di Mauro M, Fratini S, et al. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovasc Diabetol 2010; 9: 89-95
75. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362-363
76. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005; 19: 567-576
77. Meinardi MT, Van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746-2753
78. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction. Clin Chem 2005; 51: 1405-1410
79. Lee HS, Son CB, Shin SH, et al. Clinical correlation between brain natriutetic peptide and anthracyclininduced cardiac toxicity. Cancer Res Treat 2008; 40: 121-126
80. Urun Y, Utkan G, Yalcin B, et al. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer. Exp Oncol 2015; 37: 53-57
81. Onitilo AA, Engel JM, Stankowski RV, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 2012; 134: 291-298
82. Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012; 30: 1050-1057
83. Lagoa R, Gañ án C, Ló pez-Sánchez C, et al. The decrease of NAD(P)H: quinone oxidoreductase 1 activity and increase of ROS production by NADPH oxidases are early biomarkers in doxorubicin cardiotoxicity. Biomarkers 2014; 19: 142-153
84. Satoh M, Nakamura M, Akatsu T, et al. C-reactive protein co-expresses with tumor necrosis factor-Alpha in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 2005; 7: 754-748
85. Hogye M, Mandi Y, Csanady M, et al. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-Alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 2004; 94: 249-251
86. Mantovani G, Madeddu C, Cadeddu C, et al. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2008; 13: 1296-1305
87. Dess M, Piras A, Madeddu C, et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Exp Ther Med 2011; 2: 1003-1100
88. Dess M, Madeddu C, Piras A, et al. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubininduced inflammation and oxidative stress assessed by serial strain rate. SpringerPlus 2013; 2: 198
89. Peetz D, Post F, Schinzel H, et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005; 43: 1351-1358
90. Stejskal D, Lacnak B, Jedelsky L, et al. Use of glycogen phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. A comparison with the ELISA method. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151: 247-249
91. O?Donoghue M, De Lemos JA, Morrow DA, et al. Prognostic utility of hearttype fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006; 114: 550-557
92. ElGhandour AH, ElSorady M, Azab S, ElRahman M. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol Rev 2009; 1: 29-32
93. Horacek JM, Tichy M, Pudil R, Jebavy L.Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Ann Oncol 2008; 19: 1656-1657
94. Horacek JM, Vasatova M, Tichy M, et al. The use of cardiac biomarkers in detection of cardioxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol 2010; 32: 97-99
95. Horie T, Ono K, Nishi H, et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010; 87: 656-664
96. Wang X, Ha T, Liu L, et al. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res 2013; 97: 432-442
97. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013; 108: 366
98. Madonna R, Cadeddu C, Deidda M, et al. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev 2015; 20: 621-631